Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: XELODA

« Back to Dashboard

Summary for Tradename: XELODA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$754,133,000

Pharmacology for Tradename: XELODA

Clinical Trials for: XELODA

LBH589 in Combination With Capecitabine Plus/Minus (┬▒) Lapatinib in Breast Cancer Patients
Status: Completed Condition: Breast Cancer

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; HER2/Neu-positive Breast Cancer

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
Status: Completed Condition: Metastatic Breast Cancer

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
Status: Recruiting Condition: Breast Cancer

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Status: Completed Condition: Advanced Solid Tumors

Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Status: Recruiting Condition: Breast Cancer

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Terminated Condition: Hepatocellular Carcinoma

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Status: Completed Condition: Pancreatic Cancer

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
Status: Recruiting Condition: Breast Neoplasms; Neoplasms by Site; Neoplasm Metastasis; Breast Diseases; Skin Diseases

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Completed Condition: Advanced Solid Tumors; Locally Advanced or Metastatic Breast or Colorectal Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXNo5,472,949*PED<disabled>Y<disabled>
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXYes5,472,949*PED<disabled>Y<disabled>
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXYes<disabled><disabled>
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXYes<disabled><disabled>
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: XELODA

Drugname Dosage Strength RLD Submissiondate
capecitabineTablets150 mg and 500 mgXeloda11/10/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc